Als Ftd Spectrum is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are now recognized as two ends of a shared clinical, genetic, and pathological spectrum rather than
separate diseases.[1] Up to 50% of ALS
patients demonstrate cognitive and/or behavioral impairment, with approximately 15% meeting full diagnostic criteria for FTD. Conversely, approximately 15% of FTD patients develop
motor neuron signs. The unifying pathological substrate is TDP-43 Proteinopathy, present in approximately 97% of ALS and approximately 50% of FTD cases. The 2011 discovery of
C9orf72 hexanucleotide repeat expansions — the most common shared genetic cause of both diseases — cemented the concept of a single ALS-FTD disease continuum. class="ref-link" data-ref-number="2" data-ref-text="Guo W et al., Editorial: Current Concept and Translational Study in ALS-FTD Spectrum: From Genetics,
neuroinflammation to Neurodegeneration (2022)" title="Guo W et al., Editorial: Current Concept and Translational Study in ALS-FTD Spectrum: From Genetics, neuroinflammation to
Neurodegeneration (2022)">2[3] class="ref-link" data-ref-number="1" data-ref-text="Seddighi S et al., Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD (2024)"
title="Seddighi S et al., Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD (2024)">1
The 2017 revised Strong criteria formalized the ALS-frontotemporal spectrum disorder (ALS-FTSD) nomenclature:[4] [2]
| Classification | Description |
|---|---|
| ALS-cn | Cognitively and behaviorally normal ALS |
| ALS-ci | ALS with cognitive impairment (executive, language, fluency) |
| ALS-bi | ALS with behavioral impairment (apathy, disinhibition) |
| ALS-cbi | ALS with combined cognitive and behavioral impairment |
| ALS-FTD | Full ALS with concurrent FTD diagnosis |
| FTD-MND | FTD presentation with motor neuron involvement |
| Pure FTD | FTD without motor neuron signs |
Ringholz et al. (2005) conducted a landmark study of 279 sporadic ALS patients, finding that 51% had evidence of cognitive impairment on non-motor tasks, with cluster analysis identifying four subgroups: 49% cognitively intact, 32% mild impairment, 13% moderate impairment, and 6% severe impairment.[5] More recent analyses using the Mild Behavioral and Neurocognitive Impairment (MBNI) framework reduce the proportion classified as cognitively normal from 46% to just 15%.
The ECAS is a validated screening tool assessing ALS-specific functions (executive, language, verbal fluency) and ALS-nonspecific functions (memory, visuospatial), plus behavioral abnormalities. It demonstrates 85% sensitivity and 85% specificity for ALS-related cognitive impairment, and 94% sensitivity and 96% specificity in FTD populations.
Mutations in at least nine genes cause both ALS and FTD, converging on three key cellular pathways: autophagy/protein degradation, [RNA processing], and [mitochondrial function].
| Gene | Protein | Pathway | Key Features |
|---|---|---|---|
| C9orf72 | C9orf72 | autophagy/RNA | GGGGCC repeat expansion; ~40% familial ALS, ~25% familial FTD |
| TARDBP | TDP-43 | RNA processing | Encodes TDP-43; mutations cause both ALS and FTLD-TDP |
| FUS | FUS | RNA processing | Causes ALS-FUS and FTLD-FUS |
| TBK1 | TBK1 | Autophagy/immunity | Loss-of-function impairs autophagy and neuroinflammation |
| SQSTM1 | p62 | Selective autophagy | Sequestosome-1 mutations impair protein degradation |
| OPTN | Optineurin | Autophagy/NF-κB | Loss-of-function affects autophagy and immune signaling |
| VCP | VCP | Proteasome/autophagy | Causes [multisystem proteinopathy] |
| UBQLN2 | Ubiquilin-2 | Proteasome | X-linked ALS-FTD with ubiquilin-2-positive inclusions |
| CHCHD10 | CHCHD10 | Mitochondria | Underscores mitochondrial dysfunction in ALS-FTD |
The landmark 2006 discovery by Neumann et al. identified ubiquitinated TDP-43 as the pathological protein in both FTLD-U and ALS, finding TDP-43 inclusions in all 53 cases of FTLD-U and 18 cases of ALS examined.[6] TDP-43 is found in approximately 97% of ALS cases and approximately 50% of FTD cases (FTLD-TDP).
Brettschneider et al. (2013) defined four neuropathological stages of sequential pTDP-43 spread in ALS:[7]
This model supports the hypothesis that pTDP-43 pathology propagates sequentially along axonal pathways, consistent with a prion-like spreading mechanism. Data-driven computational approaches (2023) have further distinguished ALS from FTLD-TDP from LATE with 85.9% cross-validated accuracy.
The GGGGCC (G4C2) hexanucleotide repeat expansion in the first intron of C9orf72 causes disease through three non-mutually-exclusive mechanisms:
C9orf72 protein functions as a guanine nucleotide exchange factor in autophagy initiation and [endolysosomal trafficking]. The repeat expansion reduces C9orf72 transcription, impairing autophagy and microglial immune function.
Both sense (G4C2) and antisense (G2C4) repeat RNA transcripts form nuclear RNA foci that sequester RNA-binding proteins, disrupting normal [RNA processing].[8] The repeat RNA adopts G-quadruplex and hairpin secondary structures.
Non-canonical repeat-associated non-ATG (RAN) translation produces five DPR species:
| DPR | Source | Toxicity | Mechanism |
|---|---|---|---|
| Poly-GA | Sense | Moderate | Most abundant; p62-positive inclusions; ER stress |
| Poly-GP | Both | Low | Used as pharmacodynamic biomarker |
| Poly-GR | Sense | High | Disrupts nucleolar function; phase separation |
| Poly-PA | Antisense | Low | Relatively less toxic |
| Poly-PR | Antisense | High | Impairs [nucleocytoplasmic transport] |
The arginine-containing DPRs (poly-GR and poly-PR) are most toxic, disrupting [stress granule] dynamics, liquid-liquid phase separation, nuclear pore function, and promoting TDP-43 aggregation.
Phenotypic heterogeneity within C9orf72 families is striking: individuals may present as pure ALS, pure FTD, ALS-FTD, or even psychiatric disorders, suggesting significant roles for genetic modifiers and environmental factors.
NfL in blood and CSF is elevated in ALS, correlating with disease severity, progression rate, and survival. Benatar et al. (2024) established NfL as a susceptibility/risk biomarker, prognostic biomarker, and pharmacodynamic biomarker — the FDA approved tofersen for SOD1-ALS based partly on NfL reduction.[9]
Seed amplification assays (SAAs): Dellarole et al. (2025) detected TDP-43 seeding activity in CSF of 67% of TDP-43-linked symptomatic patients with 93% specificity; almost half of presymptomatic subjects tested positive.[10]
Cryptic exon biomarkers: Loss of TDP-43 nuclear function leads to erroneous inclusion of cryptic exons in STMN2, UNC13A, and HDGFL2 transcripts. Irwin et al. (2024) showed that cryptic HDGFL2 protein is detectable in CSF earlier than NfL, including in presymptomatic C9orf72 carriers.[11]
Plasma extracellular vesicle biomarkers: Chatterjee et al. (2024) demonstrated that plasma EVs contain quantifiable TDP-43 and full-length tau] (including 3R and 4R isoforms), discriminating between diagnostic groups with AUC >0.9 in a cohort of 704 patients.[12]
MRI shows frontal and temporal lobe atrophy patterns varying by pathological subtype. ALS-specific changes involve motor cortex and anterior cingulate, while ALS-FTD shows widespread frontal and temporal grey and white matter changes. Tau PET](/technologies/pet-imaging) holds promise but is limited by lack of radioligands detecting the full range of tau isoforms in FTD.
The gold standard is multidisciplinary team care including neurologists, respiratory therapists, nutritionists, physical/occupational/speech therapists, psychologists, social workers, and palliative care. The 2024 European Academy of Neurology (EAN) guideline provides comprehensive evidence-based recommendations.[13]
The combination of ALS and FTD significantly worsens prognosis:
| Presentation | Median Survival |
|---|---|
| Pure ALS | 3–5 years from symptom onset |
| Pure FTD | ~7.5 years |
| ALS-FTD | 2–3 years — worse than either alone |
Even executive dysfunction below the FTD threshold independently predicts shorter survival in ALS. Cognitive impairment also reduces compliance with life-sustaining interventions such as gastrostomy and noninvasive ventilation.
Current models debate trans-synaptic spread versus region-specific vulnerability, and whether propagation differs between spinal, bulbar, and frontal trajectories.
Which factors determine phenotypic divergence in C9orf72 expansion carriers?
Despite a shared mutation, patients can present with predominantly motor disease, cognitive-behavioral syndromes, or mixed phenotypes, implying strong genetic and cell-type modifiers.
What is the causal contribution of C9orf72 dipeptide repeat species to neurodegeneration?
Relative toxicity of poly-GA, poly-GR, and poly-PR remains unresolved in human tissue and longitudinal biomarker studies.
Can neuroimmune programs predict progression across the ALS-FTD continuum?
Whether microglia and astrocytes are drivers versus responders at each disease stage remains uncertain and directly impacts trial stratification.
What biomarker combination best captures disease-stage transitions?
Integrating neurofilament light chain, fluid TDP-43 assays, and advanced MRI/PET markers for shared staging is still an active translational gap.\n\n## See Also\n\n- Amyotrophic Lateral Sclerosis
Which factors determine phenotypic divergence in C9orf72 expansion carriers?
Despite a shared mutation, patients can present with predominantly motor disease, cognitive-behavioral syndromes, or mixed phenotypes, implying strong genetic and cell-type modifiers.
What is the causal contribution of C9orf72 dipeptide repeat species to neurodegeneration?
Relative toxicity of poly-GA, poly-GR, and poly-PR remains unresolved in human tissue and longitudinal biomarker studies.
Can neuroimmune programs predict progression across the ALS-FTD continuum?
Whether microglia and astrocytes are drivers versus responders at each disease stage remains uncertain and directly impacts trial stratification.
What biomarker combination best captures disease-stage transitions?
Integrating neurofilament light chain, fluid TDP-43 assays, and advanced MRI/PET markers for shared staging is still an active translational gap.\n\n## See Also\n\n- Amyotrophic Lateral Sclerosis
Neurofilament Light Chain (NfL)\n\n## External Links
The following resources provide additional data on genes and proteins related to Amyotrophic Lateral Sclerosis (ALS):
The study of Als Ftd Spectrum has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.